Clinical, Biochemical, and Genetic Characteristics of “Nonclassic” Apparent Mineralocorticoid Excess Syndrome
Abstract Context Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder, caused by severe 11β-hydroxysteroid dehydrogenase type 2 enzyme (11β-HSD2) deficiency. AME manifests as low-renin pediatric hypertension, hypokalemia and high cortisol/cortisone (F/E) ratio. Objective To...
Saved in:
Published in | The journal of clinical endocrinology and metabolism Vol. 104; no. 2; pp. 595 - 603 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Washington, DC
Endocrine Society
01.02.2019
Copyright Oxford University Press Oxford University Press |
Subjects | |
Online Access | Get full text |
ISSN | 0021-972X 1945-7197 1945-7197 |
DOI | 10.1210/jc.2018-01197 |
Cover
Loading…
Abstract | Abstract
Context
Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder, caused by severe 11β-hydroxysteroid dehydrogenase type 2 enzyme (11β-HSD2) deficiency. AME manifests as low-renin pediatric hypertension, hypokalemia and high cortisol/cortisone (F/E) ratio.
Objective
To evaluate nonclassic AME (NC-AME) due to partial 11β-HSD2 insufficiency and its association with hypertension, mineralocorticoid receptor (MR) activation, and inflammatory parameters.
Design
Cross-sectional study.
Setting
Primary care cohort.
Participants
We recruited 127 adolescents and adults. Subjects with secondary hypertension were excluded. We measured clinical, biochemical, renal, vascular, and inflammatory variables. Sequencing of HSD11B2 gene was performed in all subjects.
Main Outcome Measure
NC-AME.
Results
Serum F/E ratio was positively associated with systolic blood pressure (BP), microalbuminuria, and high-sensitivity C-reactive protein (hs-CRP). Serum cortisone correlated with MR activation parameters even when adjusted for age, body mass index, and sex: lower cortisone with higher potassium excretion (partial r = −0.29, P = 0.002) and with lower plasma renin activity (PRA) (partial r = 0.29, P = 0.001). Consistently, we identified 9 in 127 subjects (7.1%) with high F/E ratios (first quartile) and low cortisone (last quartile), suggestive of NC-AME. These subjects had higher systolic BP, 141.4 ± 25.7 mm Hg vs 127.3 ± 18.1 mm Hg, P = 0.03; lower PRA, 0.36 ± 0.19 ng/L*s vs 0.64 ± 0.47 ng/L*s, P < 0.0001; and greater potassium excretion, microalbuminuria, hs-CRP, and plasminogen activator inhibitor. We only found in 2 out of 9 subjects with NC-AME heterozygous mutations in the HSD11B2 gene.
Conclusions
These findings suggest a spectrum of partial 11β-HSD2 insufficiency in a primary care cohort without the classic phenotype and genotype of AME. NC-AME may represent a phenotype of MR activation and cardiovascular risk, suggesting that these subjects could be treated with MR antagonists.
Our findings demonstrate that nonclassic AME may represent a currently unrecognized phenotype of excess MR activation and cardiovascular risk that may be specifically targeted with MR antagonists. |
---|---|
AbstractList | Context: Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder, caused by severe 11[beta]-hydroxysteroid dehydrogenase type 2 enzyme (11[beta]-HSD2) deficiency. AME manifests as low-renin pediatric hypertension, hypokalemia and high cortisol/cortisone (F/E) ratio. Objective: To evaluate nonclassic AME (NC-AME) due to partial 11[beta]-HSD2 insufficiency and its association with hypertension, mineralocorticoid receptor (MR) activation, and inflammatory parameters. Design: Cross-sectional study. Setting: Primary care cohort. Participants: We recruited 127 adolescents and adults. Subjects with secondary hypertension were excluded. We measured clinical, biochemical, renal, vascular, and inflammatory variables. Sequencing of HSD11B2 gene was performed in all subjects. Main Outcome Measure: NC-AME. Results: Serum F/E ratio was positively associated with systolic blood pressure (BP), microalbuminuria, and high-sensitivity C-reactive protein (hs-CRP). Serum cortisone correlated with MR activation parameters even when adjusted for age, body mass index, and sex: lower cortisone with higher potassium excretion (partial r = -0.29, P = 0.002) and with lower plasma renin activity (PRA) (partial r = 0.29, P = 0.001). Consistently, we identified 9 in 127 subjects (7.1%) with high F/E ratios (first quartile) and low cortisone (last quartile), suggestive of NC-AME. These subjects had higher systolic BP, 141.4 [+ or -] 25.7 mm Hg vs 127.3 [+ or -] 18.1 mm Hg, P = 0.03; lower PRA, 0.36 [+ or -] 0.19 ng/L*s vs 0.64 [+ or -] 0.47 ng/L*s, P < 0.0001; and greater potassium excretion, microalbuminuria, hs-CRP, and plasminogen activator inhibitor. We only found in 2 out of 9 subjects with NC-AME heterozygous mutations in the HSD11B2 gene. Conclusions: These findings suggest a spectrum of partial 11[beta]-HSD2 insufficiency in a primary care cohort without the classic phenotype and genotype of AME. NC-AME may represent a phenotype of MR activation and cardiovascular risk, suggesting that these subjects could be treated with MR antagonists. (J Clin Endocrinol Metab 104: 595-603, 2019) Abstract Context Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder, caused by severe 11β-hydroxysteroid dehydrogenase type 2 enzyme (11β-HSD2) deficiency. AME manifests as low-renin pediatric hypertension, hypokalemia and high cortisol/cortisone (F/E) ratio. Objective To evaluate nonclassic AME (NC-AME) due to partial 11β-HSD2 insufficiency and its association with hypertension, mineralocorticoid receptor (MR) activation, and inflammatory parameters. Design Cross-sectional study. Setting Primary care cohort. Participants We recruited 127 adolescents and adults. Subjects with secondary hypertension were excluded. We measured clinical, biochemical, renal, vascular, and inflammatory variables. Sequencing of HSD11B2 gene was performed in all subjects. Main Outcome Measure NC-AME. Results Serum F/E ratio was positively associated with systolic blood pressure (BP), microalbuminuria, and high-sensitivity C-reactive protein (hs-CRP). Serum cortisone correlated with MR activation parameters even when adjusted for age, body mass index, and sex: lower cortisone with higher potassium excretion (partial r = −0.29, P = 0.002) and with lower plasma renin activity (PRA) (partial r = 0.29, P = 0.001). Consistently, we identified 9 in 127 subjects (7.1%) with high F/E ratios (first quartile) and low cortisone (last quartile), suggestive of NC-AME. These subjects had higher systolic BP, 141.4 ± 25.7 mm Hg vs 127.3 ± 18.1 mm Hg, P = 0.03; lower PRA, 0.36 ± 0.19 ng/L*s vs 0.64 ± 0.47 ng/L*s, P < 0.0001; and greater potassium excretion, microalbuminuria, hs-CRP, and plasminogen activator inhibitor. We only found in 2 out of 9 subjects with NC-AME heterozygous mutations in the HSD11B2 gene. Conclusions These findings suggest a spectrum of partial 11β-HSD2 insufficiency in a primary care cohort without the classic phenotype and genotype of AME. NC-AME may represent a phenotype of MR activation and cardiovascular risk, suggesting that these subjects could be treated with MR antagonists. Our findings demonstrate that nonclassic AME may represent a currently unrecognized phenotype of excess MR activation and cardiovascular risk that may be specifically targeted with MR antagonists. Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder, caused by severe 11β-hydroxysteroid dehydrogenase type 2 enzyme (11β-HSD2) deficiency. AME manifests as low-renin pediatric hypertension, hypokalemia and high cortisol/cortisone (F/E) ratio. To evaluate nonclassic AME (NC-AME) due to partial 11β-HSD2 insufficiency and its association with hypertension, mineralocorticoid receptor (MR) activation, and inflammatory parameters. Cross-sectional study. Primary care cohort. We recruited 127 adolescents and adults. Subjects with secondary hypertension were excluded. We measured clinical, biochemical, renal, vascular, and inflammatory variables. Sequencing of HSD11B2 gene was performed in all subjects. NC-AME. Serum F/E ratio was positively associated with systolic blood pressure (BP), microalbuminuria, and high-sensitivity C-reactive protein (hs-CRP). Serum cortisone correlated with MR activation parameters even when adjusted for age, body mass index, and sex: lower cortisone with higher potassium excretion (partial r = -0.29, P = 0.002) and with lower plasma renin activity (PRA) (partial r = 0.29, P = 0.001). Consistently, we identified 9 in 127 subjects (7.1%) with high F/E ratios (first quartile) and low cortisone (last quartile), suggestive of NC-AME. These subjects had higher systolic BP, 141.4 ± 25.7 mm Hg vs 127.3 ± 18.1 mm Hg, P = 0.03; lower PRA, 0.36 ± 0.19 ng/L*s vs 0.64 ± 0.47 ng/L*s, P < 0.0001; and greater potassium excretion, microalbuminuria, hs-CRP, and plasminogen activator inhibitor. We only found in 2 out of 9 subjects with NC-AME heterozygous mutations in the HSD11B2 gene. These findings suggest a spectrum of partial 11β-HSD2 insufficiency in a primary care cohort without the classic phenotype and genotype of AME. NC-AME may represent a phenotype of MR activation and cardiovascular risk, suggesting that these subjects could be treated with MR antagonists. Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder, caused by severe 11β-hydroxysteroid dehydrogenase type 2 enzyme (11β-HSD2) deficiency. AME manifests as low-renin pediatric hypertension, hypokalemia and high cortisol/cortisone (F/E) ratio.ContextClassical apparent mineralocorticoid excess (AME) is a rare recessive disorder, caused by severe 11β-hydroxysteroid dehydrogenase type 2 enzyme (11β-HSD2) deficiency. AME manifests as low-renin pediatric hypertension, hypokalemia and high cortisol/cortisone (F/E) ratio.To evaluate nonclassic AME (NC-AME) due to partial 11β-HSD2 insufficiency and its association with hypertension, mineralocorticoid receptor (MR) activation, and inflammatory parameters.ObjectiveTo evaluate nonclassic AME (NC-AME) due to partial 11β-HSD2 insufficiency and its association with hypertension, mineralocorticoid receptor (MR) activation, and inflammatory parameters.Cross-sectional study.DesignCross-sectional study.Primary care cohort.SettingPrimary care cohort.We recruited 127 adolescents and adults. Subjects with secondary hypertension were excluded. We measured clinical, biochemical, renal, vascular, and inflammatory variables. Sequencing of HSD11B2 gene was performed in all subjects.ParticipantsWe recruited 127 adolescents and adults. Subjects with secondary hypertension were excluded. We measured clinical, biochemical, renal, vascular, and inflammatory variables. Sequencing of HSD11B2 gene was performed in all subjects.NC-AME.Main Outcome MeasureNC-AME.Serum F/E ratio was positively associated with systolic blood pressure (BP), microalbuminuria, and high-sensitivity C-reactive protein (hs-CRP). Serum cortisone correlated with MR activation parameters even when adjusted for age, body mass index, and sex: lower cortisone with higher potassium excretion (partial r = -0.29, P = 0.002) and with lower plasma renin activity (PRA) (partial r = 0.29, P = 0.001). Consistently, we identified 9 in 127 subjects (7.1%) with high F/E ratios (first quartile) and low cortisone (last quartile), suggestive of NC-AME. These subjects had higher systolic BP, 141.4 ± 25.7 mm Hg vs 127.3 ± 18.1 mm Hg, P = 0.03; lower PRA, 0.36 ± 0.19 ng/L*s vs 0.64 ± 0.47 ng/L*s, P < 0.0001; and greater potassium excretion, microalbuminuria, hs-CRP, and plasminogen activator inhibitor. We only found in 2 out of 9 subjects with NC-AME heterozygous mutations in the HSD11B2 gene.ResultsSerum F/E ratio was positively associated with systolic blood pressure (BP), microalbuminuria, and high-sensitivity C-reactive protein (hs-CRP). Serum cortisone correlated with MR activation parameters even when adjusted for age, body mass index, and sex: lower cortisone with higher potassium excretion (partial r = -0.29, P = 0.002) and with lower plasma renin activity (PRA) (partial r = 0.29, P = 0.001). Consistently, we identified 9 in 127 subjects (7.1%) with high F/E ratios (first quartile) and low cortisone (last quartile), suggestive of NC-AME. These subjects had higher systolic BP, 141.4 ± 25.7 mm Hg vs 127.3 ± 18.1 mm Hg, P = 0.03; lower PRA, 0.36 ± 0.19 ng/L*s vs 0.64 ± 0.47 ng/L*s, P < 0.0001; and greater potassium excretion, microalbuminuria, hs-CRP, and plasminogen activator inhibitor. We only found in 2 out of 9 subjects with NC-AME heterozygous mutations in the HSD11B2 gene.These findings suggest a spectrum of partial 11β-HSD2 insufficiency in a primary care cohort without the classic phenotype and genotype of AME. NC-AME may represent a phenotype of MR activation and cardiovascular risk, suggesting that these subjects could be treated with MR antagonists.ConclusionsThese findings suggest a spectrum of partial 11β-HSD2 insufficiency in a primary care cohort without the classic phenotype and genotype of AME. NC-AME may represent a phenotype of MR activation and cardiovascular risk, suggesting that these subjects could be treated with MR antagonists. Context Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder, caused by severe 11β-hydroxysteroid dehydrogenase type 2 enzyme (11β-HSD2) deficiency. AME manifests as low-renin pediatric hypertension, hypokalemia and high cortisol/cortisone (F/E) ratio. Objective To evaluate nonclassic AME (NC-AME) due to partial 11β-HSD2 insufficiency and its association with hypertension, mineralocorticoid receptor (MR) activation, and inflammatory parameters. Design Cross-sectional study. Setting Primary care cohort. Participants We recruited 127 adolescents and adults. Subjects with secondary hypertension were excluded. We measured clinical, biochemical, renal, vascular, and inflammatory variables. Sequencing of HSD11B2 gene was performed in all subjects. Main Outcome Measure NC-AME. Results Serum F/E ratio was positively associated with systolic blood pressure (BP), microalbuminuria, and high-sensitivity C-reactive protein (hs-CRP). Serum cortisone correlated with MR activation parameters even when adjusted for age, body mass index, and sex: lower cortisone with higher potassium excretion (partial r = −0.29, P = 0.002) and with lower plasma renin activity (PRA) (partial r = 0.29, P = 0.001). Consistently, we identified 9 in 127 subjects (7.1%) with high F/E ratios (first quartile) and low cortisone (last quartile), suggestive of NC-AME. These subjects had higher systolic BP, 141.4 ± 25.7 mm Hg vs 127.3 ± 18.1 mm Hg, P = 0.03; lower PRA, 0.36 ± 0.19 ng/L*s vs 0.64 ± 0.47 ng/L*s, P < 0.0001; and greater potassium excretion, microalbuminuria, hs-CRP, and plasminogen activator inhibitor. We only found in 2 out of 9 subjects with NC-AME heterozygous mutations in the HSD11B2 gene. Conclusions These findings suggest a spectrum of partial 11β-HSD2 insufficiency in a primary care cohort without the classic phenotype and genotype of AME. NC-AME may represent a phenotype of MR activation and cardiovascular risk, suggesting that these subjects could be treated with MR antagonists. |
Audience | Academic |
Author | Lagos, Carlos F Campino, Carmen Martínez-Aguayo, Alejandro García, Hernán Valdivia, Carolina Fardella, Carlos E Tapia-Castillo, Alejandra Solari, Sandra Allende, Fidel Vecchiola, Andrea Vaidya, Anand Baudrand, Rene Carvajal, Cristian A Fuentes, Cristóbal A |
AuthorAffiliation | Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile Center for Genetics and Genomics, School of Medicine, Clínica Alemana-Universidad del Desarrollo, Lo Barnechea, Chile Millennium Institute on Immunology and Immunotherapy (IMII), Santiago, Chile Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts Department of Clinical Laboratories, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile Facultad de Medicina y Ciencia, Universidad San Sebastián, Campus Los Leones, Santiago, Chile Endocrinology Pediatrics Division, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile |
AuthorAffiliation_xml | – name: Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile Center for Genetics and Genomics, School of Medicine, Clínica Alemana-Universidad del Desarrollo, Lo Barnechea, Chile Millennium Institute on Immunology and Immunotherapy (IMII), Santiago, Chile Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts Department of Clinical Laboratories, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile Facultad de Medicina y Ciencia, Universidad San Sebastián, Campus Los Leones, Santiago, Chile Endocrinology Pediatrics Division, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile |
Author_xml | – sequence: 1 givenname: Alejandra orcidid: 0000-0002-6081-1468 surname: Tapia-Castillo fullname: Tapia-Castillo, Alejandra organization: Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile – sequence: 2 givenname: Rene surname: Baudrand fullname: Baudrand, Rene organization: Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile – sequence: 3 givenname: Anand surname: Vaidya fullname: Vaidya, Anand organization: Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts – sequence: 4 givenname: Carmen surname: Campino fullname: Campino, Carmen organization: Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile – sequence: 5 givenname: Fidel surname: Allende fullname: Allende, Fidel organization: Department of Clinical Laboratories, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile – sequence: 6 givenname: Carolina surname: Valdivia fullname: Valdivia, Carolina organization: Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile – sequence: 7 givenname: Andrea surname: Vecchiola fullname: Vecchiola, Andrea organization: Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile – sequence: 8 givenname: Carlos F surname: Lagos fullname: Lagos, Carlos F organization: Millennium Institute on Immunology and Immunotherapy (IMII), Santiago, Chile – sequence: 9 givenname: Cristóbal A surname: Fuentes fullname: Fuentes, Cristóbal A organization: Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile – sequence: 10 givenname: Sandra surname: Solari fullname: Solari, Sandra organization: Facultad de Medicina y Ciencia, Universidad San Sebastián, Campus Los Leones, Santiago, Chile – sequence: 11 givenname: Alejandro surname: Martínez-Aguayo fullname: Martínez-Aguayo, Alejandro organization: Endocrinology Pediatrics Division, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile – sequence: 12 givenname: Hernán surname: García fullname: García, Hernán organization: Endocrinology Pediatrics Division, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile – sequence: 13 givenname: Cristian A surname: Carvajal fullname: Carvajal, Cristian A email: ccarvaja@med.puc.cl organization: Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile – sequence: 14 givenname: Carlos E surname: Fardella fullname: Fardella, Carlos E email: cfardella@med.puc.cl organization: Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30239803$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kk1vEzEQhi1URNPCkStaiQuHbvDHfvkYolKQChwAiZvl9Y6Jg9dO7V2V3vpDyp_rL8FLEiEiah_ssZ739WhmTtCR8w4Qek7wnFCCX6_VnGLS5JgQXj9CM8KLMq_T_QjNMKYk5zX9doxOYlxjTIqiZE_QMcOU8QazGbpaWuOMkvYse2O8WkG_DaTrsgtwMBiVLVcySDVAMDGFMfM6u7-9--idsjJGo-5vf2WLzUYGcEP2wTgI0nrlQ4K96bLznwpizD7fuC74Hp6ix1raCM925yn6-vb8y_Jdfvnp4v1ycZmromJ1rhnWqmEa2qJqmNQlL3RNWsYB84JUvC6h4VVdkkJhWbQl4y0mTGnKgADUjJ2iV1vfTfBXI8RB9CYqsFY68GMUlKRVUl6WCX15gK79GFzKTlBWFbSuywr_pb5LC8I47YdUlslULCpMOUt5TtT8P1Ta3VTa1Dtt0vs_ghe7z8e2h05sgulluBH7HiWAbQEVfIwBtFBmkIPxLjkbKwgW0ySItRLTJIg_k5BU-YFqb_wQT7b8tbep1fGHHa8hiBVIO6wONflesyuxHzcP2e_Q3w76z5s |
CitedBy_id | crossref_primary_10_1007_s12020_021_02783_1 crossref_primary_10_1093_ejendo_lvae049 crossref_primary_10_1186_s12967_022_03698_9 crossref_primary_10_1016_j_ecl_2019_08_010 crossref_primary_10_1007_s12020_020_02460_9 crossref_primary_10_1210_clinem_dgae663 crossref_primary_10_1016_j_endinu_2019_09_005 crossref_primary_10_1016_j_mce_2021_111210 crossref_primary_10_1210_jc_2019_00800 crossref_primary_10_1007_s12020_022_03103_x crossref_primary_10_1007_s11906_020_01108_3 crossref_primary_10_1007_s12020_021_02938_0 crossref_primary_10_1016_j_endien_2019_09_005 crossref_primary_10_7759_cureus_11656 crossref_primary_10_1161_HYPERTENSIONAHA_124_23385 crossref_primary_10_3389_fendo_2024_1491825 crossref_primary_10_1016_j_ppedcard_2022_101581 crossref_primary_10_1210_jendso_bvae113 crossref_primary_10_1210_clinem_dgz315 crossref_primary_10_3389_fendo_2023_1155011 crossref_primary_10_1186_s12967_019_02143_8 crossref_primary_10_3389_fendo_2021_681974 crossref_primary_10_1016_j_mce_2021_111168 crossref_primary_10_1093_ajh_hpz023 crossref_primary_10_1210_jendso_bvae051 crossref_primary_10_3389_fped_2020_543309 crossref_primary_10_3389_fimmu_2021_768734 crossref_primary_10_1038_s41598_021_96628_6 |
Cites_doi | 10.1161/HYPERTENSIONAHA.116.08952 10.1016/j.jsbmb.2016.03.010 10.1016/S2213-8587(18)30071-8 10.1097/00004872-200501000-00015 10.1016/j.jsbmb.2007.03.020 10.1001/jama.2015.10081 10.1542/peds.114.2.S2.555 10.3390/ijms19020546 10.1210/jc.2002-021909 10.1093/ndt/gfq197 10.7326/M17-0882 10.1161/01.HYP.0000013784.18175.51 10.2169/internalmedicine.47.1165 10.1111/j.1365-2265.2007.02898.x 10.1093/ajh/hpt277 10.1016/j.jacc.2017.11.006 10.1111/j.1365-2265.2011.04308.x 10.1161/CIRCULATIONAHA.107.690396 10.1161/01.HYP.27.6.1193 10.1093/nar/19.19.5444 10.1038/jhh.2012.67 10.1093/ajh/hpy051 10.1210/jc.2008-0125 10.1111/j.1365-2265.1985.tb00160.x 10.1016/j.mce.2014.08.003 10.1126/science.3037703 10.1016/j.bbadis.2009.10.017 10.1161/HYPERTENSIONAHA.116.08966 10.1038/ajh.2011.263 10.1093/ajh/hpx065 10.1007/s12020-009-9269-9 10.1093/ajh/hps080 10.1097/HJH.0000000000001017 10.1053/meta.2001.24213 10.1007/BF03346533 10.1210/en.2010-0925 10.1016/j.beem.2011.11.006 10.1542/peds.2017-1904 10.1038/ng0895-394 10.1093/ajh/hpt091 10.1152/physiolgenomics.00053.2010 10.1210/jc.2016-3867 10.1210/jc.2015-4061 10.1093/ajh/hpw056 |
ContentType | Journal Article |
Copyright | Copyright © 2019 Endocrine Society 2019 Copyright © Oxford University Press 2015 COPYRIGHT 2019 Oxford University Press Copyright © 2019 Endocrine Society. |
Copyright_xml | – notice: Copyright © 2019 Endocrine Society 2019 – notice: Copyright © Oxford University Press 2015 – notice: COPYRIGHT 2019 Oxford University Press – notice: Copyright © 2019 Endocrine Society. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7T5 7TM 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1210/jc.2018-01197 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest One Academic Middle East (New) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1945-7197 |
EndPage | 603 |
ExternalDocumentID | A602936830 30239803 10_1210_jc_2018_01197 10.1210/jc.2018-01197 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Chile |
GeographicLocations_xml | – name: Chile |
GrantInformation_xml | – fundername: Fondo Nacional de Desarrollo CientÃ-fico y TecnolÃ3gico grantid: 1150437; 1160695; 1160836; 150023 funderid: 10.13039/501100002850 – fundername: Instituto Milenio en InmunologÃ-a e Inmunoterapia grantid: P09/16-F – fundername: CETREN-UC |
GroupedDBID | --- -~X .55 .GJ .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 3O- 4.4 48X 53G 5GY 5RS 5YH 7X7 88E 8F7 8FI 8FJ AABZA AACZT AAIMJ AAJQQ AAKAS AAPGJ AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL AAYJJ ABBLC ABDFA ABDPE ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABUWG ABVGC ABWST ABXVV ABXZS ACFRR ACGFO ACGFS ACPRK ACUTJ ACVCV ACYHN ACZBC ADBBV ADGKP ADGZP ADHKW ADMTO ADNBA ADQBN ADRTK ADVEK ADZCM AELWJ AEMDU AEMQT AENEX AENZO AERZD AETBJ AEWNT AFCHL AFFNX AFFQV AFFZL AFGWE AFKRA AFOFC AFRAH AFXAL AFYAG AGINJ AGKRT AGMDO AGQXC AGUTN AHMBA AHMMS AI. AJDVS AJEEA ALMA_UNASSIGNED_HOLDINGS ALXQX APIBT APJGH AQDSO AQKUS ARIXL ASPBG ATGXG AVNTJ AVWKF AZFZN BAWUL BAYMD BCRHZ BENPR BEYMZ BPHCQ BSWAC BTRTY BVXVI C45 CCPQU CDBKE CS3 D-I DAKXR DIK E3Z EBS EIHJH EJD EMOBN ENERS F5P FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK FYUFA GAUVT GJXCC GX1 H13 HMCUK HVGLF HZ~ H~9 IAO IHR INH ITC J5H KBUDW KOP KSI KSN L7B M1P M5~ MBLQV MHKGH MJL N4W N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBFPC OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G PHGZT PQQKQ PROAC PSQYO REU ROX ROZ TEORI TJX TLC TMA TR2 TWZ UKHRP VH1 VVN W8F WHG WOQ X52 X7M YBU YFH YHG YOC YSK ZGI ZXP ZY1 ~02 ~H1 AEOTA AGORE AHGBF AJBYB NU- PHGZM AAYXX CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7QP 7T5 7TM 7XB 8FK H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c4637-f30fc83feb4683af594f71b39e09416975e8967514c0a4b539b013cf23e1ee733 |
IEDL.DBID | 7X7 |
ISSN | 0021-972X 1945-7197 |
IngestDate | Fri Jul 11 07:21:18 EDT 2025 Sun Jul 20 16:10:14 EDT 2025 Tue Jun 17 21:12:19 EDT 2025 Tue Jun 10 20:45:51 EDT 2025 Thu Apr 03 07:11:00 EDT 2025 Tue Jul 01 01:10:50 EDT 2025 Thu Apr 24 23:10:59 EDT 2025 Fri May 16 03:53:32 EDT 2025 Wed Apr 02 07:04:42 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4637-f30fc83feb4683af594f71b39e09416975e8967514c0a4b539b013cf23e1ee733 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-6081-1468 |
PMID | 30239803 |
PQID | 2364277560 |
PQPubID | 2046206 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2111152955 proquest_journals_2364277560 gale_infotracmisc_A602936830 gale_infotracacademiconefile_A602936830 pubmed_primary_30239803 crossref_citationtrail_10_1210_jc_2018_01197 crossref_primary_10_1210_jc_2018_01197 wolterskluwer_health_10_1210_jc_2018-01197 oup_primary_10_1210_jc_2018-01197 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-February |
PublicationDateYYYYMMDD | 2019-02-01 |
PublicationDate_xml | – month: 02 year: 2019 text: 2019-February |
PublicationDecade | 2010 |
PublicationPlace | Washington, DC |
PublicationPlace_xml | – name: Washington, DC – name: United States – name: Washington |
PublicationTitle | The journal of clinical endocrinology and metabolism |
PublicationTitleAlternate | J Clin Endocrinol Metab |
PublicationYear | 2019 |
Publisher | Endocrine Society Copyright Oxford University Press Oxford University Press |
Publisher_xml | – name: Endocrine Society – name: Copyright Oxford University Press – name: Oxford University Press |
References | Flynn (2019041117530940400_B18) 2017; 140 Deuchar (2019041117530940400_B39) 2011; 152 Carvajal (2019041117530940400_B11) 2005; 23 Martinez-Aguayo (2019041117530940400_B21) 2012; 76 Carvajal (2019041117530940400_B37) 2009; 32 Carvajal (2019041117530940400_B3) 2003; 88 Nieman (2019041117530940400_B16) 2008; 93 National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2019041117530940400_B19) 2004; 114 Arriza (2019041117530940400_B1) 1987; 237 Fisher (2019041117530940400_B34) 2002; 39 Campino (2019041117530940400_B45) 2012; 25 Kosicka (2019041117530940400_B5) 2013; 27 Baudrand (2019041117530940400_B8) 2017; 69 Tapia-Castillo (2019041117530940400_B12) 2017; 30 Whelton (2019041117530940400_B17) 2018; 71 Campino (2019041117530940400_B13) 2010; 37 Stehr (2019041117530940400_B36) 2008; 136 Manning (2019041117530940400_B43) 2010; 42 Funder (2019041117530940400_B4) 2017; 165 Ueda (2019041117530940400_B40) 2017; 70 Campino (2019041117530940400_B24) 2016; 29 Brown (2019041117530940400_B9) 2017; 167 Williams (2019041117530940400_B31) 2018; 6 Campino (2019041117530940400_B14) 2013; 26 Adlin (2019041117530940400_B35) 2013; 26 Mulatero (2019041117530940400_B29) 2007; 67 Hundemer (2019041117530940400_B32) 2017; 102 Hood (2019041117530940400_B33) 2007; 116 Kawarazaki (2019041117530940400_B41) 2010; 25 Ferrari (2019041117530940400_B2) 2010; 1802 Morris (2019041117530940400_B15) 2007; 104 Shackleton (2019041117530940400_B27) 1985; 22 Funder (2019041117530940400_B6) 2016; 101 Ito (2019041117530940400_B7) 2012; 26 Tapia-Castillo (2019041117530940400_B26) 2014; 27 Baudrand (2019041117530940400_B30) 2018; 19 Inada (2019041117530940400_B20) 2008; 47 Mune (2019041117530940400_B28) 1995; 10 Mune (2019041117530940400_B44) 1996; 27 Martinez-Aguayo (2019041117530940400_B23) 2016; 34 Homma (2019041117530940400_B22) 2001; 50 Bakris (2019041117530940400_B42) 2015; 314 Carvajal (2019041117530940400_B10) 2018; 31 Lahiri (2019041117530940400_B25) 1991; 19 Zhang (2019041117530940400_B38) 2014; 395 30844046 - J Clin Endocrinol Metab. 2019 May 1;104(5):1679 |
References_xml | – volume: 69 start-page: 950 issue: 5 year: 2017 ident: 2019041117530940400_B8 article-title: Continuum of renin-independent aldosteronism in normotension publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.116.08952 – volume: 165 start-page: 151 year: 2017 ident: 2019041117530940400_B4 article-title: Apparent mineralocorticoid excess publication-title: J Steroid Biochem Mol Biol doi: 10.1016/j.jsbmb.2016.03.010 – volume: 6 start-page: 464 issue: 6 year: 2018 ident: 2019041117530940400_B31 article-title: Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(18)30071-8 – volume: 23 start-page: 71 issue: 1 year: 2005 ident: 2019041117530940400_B11 article-title: Biochemical and genetic characterization of 11 beta-hydroxysteroid dehydrogenase type 2 in low-renin essential hypertensives publication-title: J Hypertens doi: 10.1097/00004872-200501000-00015 – volume: 104 start-page: 161 issue: 3–5 year: 2007 ident: 2019041117530940400_B15 article-title: Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol publication-title: J Steroid Biochem Mol Biol doi: 10.1016/j.jsbmb.2007.03.020 – volume: 314 start-page: 884 issue: 9 year: 2015 ident: 2019041117530940400_B42 article-title: Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2015.10081 – volume: 114 start-page: 555 issue: 2 year: 2004 ident: 2019041117530940400_B19 article-title: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents publication-title: Pediatrics doi: 10.1542/peds.114.2.S2.555 – volume: 19 start-page: E546 issue: 2 year: 2018 ident: 2019041117530940400_B30 article-title: The low-renin hypertension phenotype: genetics and the role of the mineralocorticoid receptor publication-title: Int J Mol Sci doi: 10.3390/ijms19020546 – volume: 88 start-page: 2501 issue: 6 year: 2003 ident: 2019041117530940400_B3 article-title: Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2002-021909 – volume: 25 start-page: 2879 issue: 9 year: 2010 ident: 2019041117530940400_B41 article-title: Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats publication-title: Nephrol Dial Transplant doi: 10.1093/ndt/gfq197 – volume: 167 start-page: 630 issue: 9 year: 2017 ident: 2019041117530940400_B9 article-title: The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study publication-title: Ann Intern Med doi: 10.7326/M17-0882 – volume: 39 start-page: 914 issue: 4 year: 2002 ident: 2019041117530940400_B34 article-title: Familial aggregation of low-renin hypertension publication-title: Hypertension doi: 10.1161/01.HYP.0000013784.18175.51 – volume: 47 start-page: 2157 issue: 24 year: 2008 ident: 2019041117530940400_B20 article-title: Spironolactone effective hypertension in the elderly due to 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) impairment: contributory role of determining serum cortisol/cortisone ratio as a marker of 11beta-HSD2 activity publication-title: Intern Med doi: 10.2169/internalmedicine.47.1165 – volume: 67 start-page: 324 issue: 3 year: 2007 ident: 2019041117530940400_B29 article-title: Diagnosis and treatment of low-renin hypertension publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2007.02898.x – volume: 136 start-page: 1134 issue: 9 year: 2008 ident: 2019041117530940400_B36 article-title: Subclinical endothelial inflammation markers in a family with type I familial hyperaldosteronism caused by a de novo mutation [in Spanish] publication-title: Rev Med Chil – volume: 27 start-page: 299 issue: 3 year: 2014 ident: 2019041117530940400_B26 article-title: Polymorphisms in the RAC1 gene are associated with hypertension risk factors in a Chilean pediatric population publication-title: Am J Hypertens doi: 10.1093/ajh/hpt277 – volume: 71 start-page: e127 issue: 19 year: 2018 ident: 2019041117530940400_B17 article-title: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in J Am Coll Cardiol. 2018;71(19):2275–2279] publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2017.11.006 – volume: 76 start-page: 713 issue: 5 year: 2012 ident: 2019041117530940400_B21 article-title: Birth weight is inversely associated with blood pressure and serum aldosterone and cortisol levels in children publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2011.04308.x – volume: 116 start-page: 268 issue: 3 year: 2007 ident: 2019041117530940400_B33 article-title: The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.107.690396 – volume: 27 start-page: 1193 issue: 6 year: 1996 ident: 2019041117530940400_B44 article-title: Apparent mineralocorticoid excess: genotype is correlated with biochemical phenotype publication-title: Hypertension doi: 10.1161/01.HYP.27.6.1193 – volume: 19 start-page: 5444 issue: 19 year: 1991 ident: 2019041117530940400_B25 article-title: A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies publication-title: Nucleic Acids Res doi: 10.1093/nar/19.19.5444 – volume: 27 start-page: 510 issue: 8 year: 2013 ident: 2019041117530940400_B5 article-title: 11β-Hydroxysteroid dehydrogenase type 2 in hypertension: comparison of phenotype and genotype analysis publication-title: J Hum Hypertens doi: 10.1038/jhh.2012.67 – volume: 31 start-page: 910 issue: 8 year: 2018 ident: 2019041117530940400_B10 article-title: Serum cortisol and cortisone as potential biomarkers of partial 11β-hydroxysteroid dehydrogenase type 2 deficiency publication-title: Am J Hypertens doi: 10.1093/ajh/hpy051 – volume: 93 start-page: 1526 issue: 5 year: 2008 ident: 2019041117530940400_B16 article-title: The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2008-0125 – volume: 22 start-page: 701 issue: 6 year: 1985 ident: 2019041117530940400_B27 article-title: Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families publication-title: Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.1985.tb00160.x – volume: 395 start-page: 61 issue: 1-2 year: 2014 ident: 2019041117530940400_B38 article-title: Aldosterone induces C-reactive protein expression via MR-ROS-MAPK-NF-κB signal pathway in rat vascular smooth muscle cells publication-title: Mol Cell Endocrinol doi: 10.1016/j.mce.2014.08.003 – volume: 237 start-page: 268 issue: 4812 year: 1987 ident: 2019041117530940400_B1 article-title: Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor publication-title: Science doi: 10.1126/science.3037703 – volume: 1802 start-page: 1178 issue: 12 year: 2010 ident: 2019041117530940400_B2 article-title: The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension publication-title: Biochim Biophys Acta doi: 10.1016/j.bbadis.2009.10.017 – volume: 70 start-page: 111 issue: 1 year: 2017 ident: 2019041117530940400_B40 article-title: Renal dysfunction induced by kidney-specific gene deletion of hsd11b2 as a primary cause of salt-dependent hypertension publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.116.08966 – volume: 25 start-page: 597 issue: 5 year: 2012 ident: 2019041117530940400_B45 article-title: 11β-hydroxysteroid dehydrogenase type 2 polymorphisms and activity in a Chilean essential hypertensive and normotensive cohort publication-title: Am J Hypertens doi: 10.1038/ajh.2011.263 – volume: 30 start-page: e6 issue: 8 year: 2017 ident: 2019041117530940400_B12 article-title: Hypertensive patients that respond to aldosterone antagonists may have a nonclassical 11β-HSD2 deficiency publication-title: Am J Hypertens doi: 10.1093/ajh/hpx065 – volume: 37 start-page: 106 issue: 1 year: 2010 ident: 2019041117530940400_B13 article-title: 11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension publication-title: Endocrine doi: 10.1007/s12020-009-9269-9 – volume: 26 start-page: 481 issue: 4 year: 2013 ident: 2019041117530940400_B14 article-title: Age-related changes in 11β-hydroxysteroid dehydrogenase type 2 activity in normotensive subjects publication-title: Am J Hypertens doi: 10.1093/ajh/hps080 – volume: 34 start-page: 1808 issue: 9 year: 2016 ident: 2019041117530940400_B23 article-title: Cortisol/cortisone ratio and matrix metalloproteinase-9 activity are associated with pediatric primary hypertension publication-title: J Hypertens doi: 10.1097/HJH.0000000000001017 – volume: 50 start-page: 801 issue: 7 year: 2001 ident: 2019041117530940400_B22 article-title: Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure publication-title: Metabolism doi: 10.1053/meta.2001.24213 – volume: 32 start-page: 759 issue: 9 year: 2009 ident: 2019041117530940400_B37 article-title: Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha publication-title: J Endocrinol Invest doi: 10.1007/BF03346533 – volume: 152 start-page: 236 issue: 1 year: 2011 ident: 2019041117530940400_B39 article-title: 11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe−/− mice publication-title: Endocrinology doi: 10.1210/en.2010-0925 – volume: 26 start-page: 485 issue: 4 year: 2012 ident: 2019041117530940400_B7 article-title: Subclinical primary aldosteronism publication-title: Best Pract Res Clin Endocrinol Metab doi: 10.1016/j.beem.2011.11.006 – volume: 140 start-page: e20171904 issue: 3 year: 2017 ident: 2019041117530940400_B18 article-title: Clinical practice guideline for screening and management of high blood pressure in children and adolescents publication-title: Pediatrics doi: 10.1542/peds.2017-1904 – volume: 10 start-page: 394 issue: 4 year: 1995 ident: 2019041117530940400_B28 article-title: Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase publication-title: Nat Genet doi: 10.1038/ng0895-394 – volume: 26 start-page: 1076 issue: 9 year: 2013 ident: 2019041117530940400_B35 article-title: Bimodal aldosterone distribution in low-renin hypertension publication-title: Am J Hypertens doi: 10.1093/ajh/hpt091 – volume: 42 start-page: 319 issue: 3 year: 2010 ident: 2019041117530940400_B43 article-title: In silico structure-function analysis of pathological variation in the HSD11B2 gene sequence publication-title: Physiol Genomics doi: 10.1152/physiolgenomics.00053.2010 – volume: 102 start-page: 1835 issue: 6 year: 2017 ident: 2019041117530940400_B32 article-title: Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2016-3867 – volume: 101 start-page: 1889 issue: 5 year: 2016 ident: 2019041117530940400_B6 article-title: The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2015-4061 – volume: 29 start-page: 1212 issue: 10 year: 2016 ident: 2019041117530940400_B24 article-title: Usefulness and pitfalls in sodium intake estimation: comparison of dietary assessment and urinary excretion in chilean children and adults publication-title: Am J Hypertens doi: 10.1093/ajh/hpw056 – reference: 30844046 - J Clin Endocrinol Metab. 2019 May 1;104(5):1679 |
SSID | ssj0014453 |
Score | 2.4383376 |
Snippet | Abstract
Context
Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder, caused by severe 11β-hydroxysteroid dehydrogenase type 2... Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder, caused by severe 11β-hydroxysteroid dehydrogenase type 2 enzyme (11β-HSD2)... Context: Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder, caused by severe 11[beta]-hydroxysteroid dehydrogenase type 2 enzyme... Context Classical apparent mineralocorticoid excess (AME) is a rare recessive disorder, caused by severe 11β-hydroxysteroid dehydrogenase type 2 enzyme... |
SourceID | proquest gale pubmed crossref wolterskluwer oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 595 |
SubjectTerms | 11-beta-Hydroxysteroid Dehydrogenase Type 2 - genetics 11β-Hydroxysteroid dehydrogenase Adolescent Adult Angiotensin II Antagonists Biochemistry Biomarkers - blood Blood pressure Body mass index C-reactive protein Cardiovascular diseases Chile Cortisol Cortisone Cortisone - blood Cross-Sectional Studies Endocrine disorders Enzymes Excretion Female Genes Genotypes Hereditary diseases HSD11B2 gene Humans Hypertension Hypokalemia Inflammation Male Middle Aged Mineralocorticoid Excess Syndrome, Apparent - blood Mineralocorticoid Excess Syndrome, Apparent - diagnosis Mineralocorticoid Excess Syndrome, Apparent - genetics Pediatrics Phenotype Phenotypes Plasminogen activator inhibitors Potassium Primary care Renin Young Adult Youth |
Title | Clinical, Biochemical, and Genetic Characteristics of “Nonclassic” Apparent Mineralocorticoid Excess Syndrome |
URI | https://www.ncbi.nlm.nih.gov/pubmed/30239803 https://www.proquest.com/docview/2364277560 https://www.proquest.com/docview/2111152955 |
Volume | 104 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9RAFD5oC2IR8d7VtYwgCtLQJJNkMk_Sli1F2EXUwr4NM5MZ2FqT1t2ij_0h-uf6SzwnmV03YH0MczIzyZnLuX4H4LWuUpMU1kfGaE7WqirSuSyi3Miq0LqsvKZE4fGkOD7JPkzzaTC4zUNY5fJMbA_qqrFkI98joPNUCLyg359fRFQ1iryroYTGbdgk6DJSvsR0pXChrhBQKCkMQaTTgLFJWSunBF-YUBxXQnhPa3dSOJl76W5rUucW3PvRkCN7_rWNY1-7jY4ewP0gRrL9ju8P4ZarH8GdcXCUP4aLgPd5tssOZlQU61v3oOuKEdI0vsYO-1jNrPHs-urXpKktSdQze331m6GQStliCzaetfDUDSqrSNzMKjb6SRkG7HOAPHgCJ0ejL4fHUaiuENms4CLyPPa25N6ZrCi59rnMvEgMlw41vqSQInelRHUiyWysM5NzSSZT61PuEucE509ho25qtw3MCWG58cKlLsuM4zquZErWjDKvdJnyAewu_6-yAXqcKmCcKVJBkB3q1Cpih2rZMYA3K_LzDnPjJsK3xCxFexH7szqkFOCsCNVK7RcxSjP4dfEAhj1K3EO21_wK2X3TYFEYbLhcDCrs87n6uyqxi1Uz9U6xa7VrLpGGbiXyp-YDeNYtotVIVLJJljH-oXe9VaW6LNh_z-T5_2fyAu4irexCy4ewsfh-6V6i5LQwO-322IHNg9Hk46c_AyMWHg |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELemTgImhPg7CgWMxB8JLSKJnT9-QGgbnTq2Vgg2qW_GdmypYyQb7TR42weBr8CH2ifhrnFKKzHe9hjlYju-O9_ZvvsdIc9UEesoNS7QWjE8rSoClYg0SLQoUqXywilMFO4P0t4-fz9Mhkvkd5MLg2GVzZo4XaiLyuAZ-WsEOo-zDAz026PjAKtG4e1qU0KjFosd--MUtmzjN9vvgL_P43iru7fZC3xVgcDwlGWBY6EzOXNW8zRnyiWCuyzSTFjY6USpyBKbC3CjI25CxXXCBB4VGhczG1mb4QEoLPnLnIGr0CLLG93Bh4-zewvOPe4lBj5k8dCjemKezAECJkYYORYhwtScFfS2YCHBbs7PXSHXTyu8Oh9_mUbOz9m_rZvkhndc6XotabfIki1vkyt9fzV_hxx7hNHDNboxwjJcX-sHVRYUsa3hM7q5iA5NK0fPz34OqtKgDz8y52e_KLjFmJ82of3RFBC7gu0xEFejgna_Y04D_eRBFu6S_UuZ-XukVValvU-ozTLDtMtsbDnXlqmwEDGen-RJofKYtclaM7_SeLBzrLlxKHHTA-yQB0YiO-SUHW3yYkZ-VKN8XET4EpklUfuhPaN8EgOMCnG05Hoagv8Efxe2SWeBErTWLLx-Cuy-qLPAd9ZphEH6lWUs_-oBNDF7ja1jtFxpqxOgQTuIN7hJm6zWQjTrCYtEiTyEGXq1IFWyzrv990ge_H8kT8jV3l5_V-5uD3YekmvwnagD2zukNfl2Yh-B3zbRj72yUPL5svXzD-aDURc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical%2C+Biochemical%2C+and+Genetic+Characteristics+of+%E2%80%9CNonclassic%E2%80%9D+Apparent+Mineralocorticoid+Excess+Syndrome&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Tapia-Castillo%2C+Alejandra&rft.au=Baudrand%2C+Rene&rft.au=Vaidya%2C+Anand&rft.au=Campino%2C+Carmen&rft.date=2019-02-01&rft.pub=Endocrine+Society&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=104&rft.issue=2&rft.spage=595&rft.epage=603&rft_id=info:doi/10.1210%2Fjc.2018-01197&rft.externalDocID=10.1210%2Fjc.2018-01197 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |